Bronchoscopic intratumoural therapies for non-small cell lung cancer

DeMaio, Antonio; Sterman, Daniel H.

doi:10.1183/16000617.0028-2020

Cited by 21 publications

(17 citation statements)

References 106 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A phase 2 trial was presented at ESMO 2021 which showed favorable survival data when used in combination with nivolumab in the second and third line treatment of advanced NSCLC ( 148 ). A plethora of approaches are currently underway which utilize intratumoral administration of various forms of immunotherapy, including gene therapies, cellular therapies, and immunostimulatory compounds are currently being evaluated ( 149 ).…”

Section: The Current Immunotherapy Landscape For the Treatment Of Nsclcmentioning

confidence: 99%

Immunotherapy in non-small cell lung cancer: Past, present, and future directions

et al. 2022

View full text Add to dashboard Cite

Many decades in the making, immunotherapy has demonstrated its ability to produce durable responses in several cancer types. In the last decade, immunotherapy has shown itself to be a viable therapeutic approach for non-small cell lung cancer (NSCLC). Several clinical trials have established the efficacy of immune checkpoint blockade (ICB), particularly in the form of anti-programmed death 1 (PD-1) antibodies, anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibodies and anti-programmed death 1 ligand (PD-L1) antibodies. Many trials have shown progression free survival (PFS) and overall survival (OS) benefit with either ICB alone or in combination with chemotherapy when compared to chemotherapy alone. The identification of biomarkers to predict response to immunotherapy continues to be evaluated. The future of immunotherapy in lung cancer continues to hold promise with the development of combination therapies, cytokine modulating therapies and cellular therapies. Lastly, we expect that innovative advances in technology, such as artificial intelligence (AI) and machine learning, will begin to play a role in the future care of patients with lung cancer.

show abstract

Section: The Current Immunotherapy Landscape For the Treatment Of Nsclcmentioning

confidence: 99%

Immunotherapy in non-small cell lung cancer: Past, present, and future directions

et al. 2022

View full text Add to dashboard Cite

show abstract

“…91 92 93 The central goal of research thus far has been to evaluate the safety and feasibility of these therapies, with the majority of side effects reported being related to the administration technique (commonly endobronchial ultrasound-guided transbronchial needle injection), or local irritation from extravasation of an antineoplastic agents into the airway or other adjacent structures. 91…”

Section: Bronchoscopic Interventions For Malignant Central Airway Obs...mentioning

confidence: 99%

“…[91][92][93] The central goal of research thus far has been to evaluate the safety and feasibility of these therapies, with the majority of side effects reported being related to the administration technique (commonly endobronchial ultrasound-guided transbronchial needle injection), or local irritation from extravasation of an antineoplastic agents into the airway or other adjacent structures. 91 There are a host of potential benefits related to bronchoscopic administration of antineoplastic agents, including the ability to reach a higher tissue concentration than with systemic administration, reduced toxicity, and potential synergy with other local therapies. 91 A multicenter, singlearm, open-label trial of 90 patients with NSCLC and MCAO published in 2016 represents the largest study to date.…”

Section: Intratumoral Antineoplastic Therapymentioning

confidence: 99%

Malignant Central Airway Obstruction: What's New?

Shaller

Filsoof

Pineda

et al. 2022

Semin Respir Crit Care Med

View full text Add to dashboard Cite

Malignant central airway obstruction (MCAO) is a debilitating and life-limiting complication that occurs in an unfortunately large number of individuals with advanced intrathoracic cancer. Although the management of MCAO is multimodal and interdisciplinary, the task of providing patients with prompt palliation falls increasingly on the shoulders of interventional pulmonologists. While a variety of tools and techniques are available for the management of malignant obstructive lesions, advancements and evolution in this therapeutic venue have been somewhat sluggish and limited when compared with other branches of interventional pulmonary medicine (e.g., the early diagnosis of peripheral lung nodules). Indeed, one pragmatic, albeit somewhat uncharitable, reading of this article's title might suggest a wry smile and shug of the shoulders as to imply that relatively little has changed in recent years. That said, the spectrum of interventions for MCAO continues to expand, even if at a less impressive clip. Herein, we present on MCAO and its endoscopic and nonendoscopic management-that which is old, that which is new, and that which is still on the horizon.

show abstract

“…Chemotherapy along with anti-angiogenic drugs or radiotherapy is also administered in the case where no gene expression is identified. Intratumoral treatment administration has been previously proposed and administered in advanced stage patients in order to shrink a large tumor that blocks an airway or where systemic therapy was not possible [13][14][15][16][17][18][19]. It has been previously investigated that the higher the expression of PD-L1 the more efficient is the immunotherapy [20].…”

Section: Introductionmentioning

confidence: 99%

Intratumoral Treatment with Chemotherapy and Immunotherapy for NSCLC with EBUS-TBNA 19G

Hohenforst-Schmidt¹,

Huang²,

Zhou³

et al. 2021

J. Cancer

View full text Add to dashboard Cite

Introduction: Immunotherapy is being used for the past five years either as first line or second line treatment with great results. Chemotherapy and radiotherapy have been also used as combination to immunotherapy to further enhance this type of treatment. Intratumoral treatment has been previously proposed as a treatment option for certain non-small cell lung cancer patients. Patients and Methods: We recruited in total seventy four patients with non-small cell lung cancer in their second line treatment who received only chemotherapy in their first line treatment with programmed death-ligand-1 ≤ 50. Only adenocarcinoma or squamous cell carcinoma, and all negative for epidermal growth factor receptor, anaplastic lymphoma kinase, proto-oncogene tyrosine-protein kinase-1 and proto-oncogene B-Raf. Data were first examined with descriptive statistics choosing frequencies for categorical variables and histograms for the continuous ones. Twenty five received only intravenous immunotherapy and forty-nine intravenous cisplatin with immunotherapy. Data were first examined with descriptive statistics choosing frequencies for categorical variables and histograms for the continuous ones.

show abstract

Bronchoscopic intratumoural therapies for non-small cell lung cancer

Cited by 21 publications

References 106 publications

Immunotherapy in non-small cell lung cancer: Past, present, and future directions

Immunotherapy in non-small cell lung cancer: Past, present, and future directions

Malignant Central Airway Obstruction: What's New?

Intratumoral Treatment with Chemotherapy and Immunotherapy for NSCLC with EBUS-TBNA 19G

Contact Info

Product

Resources

About